Biao He, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Biao He, PhD

Associate Adjunct Professor, Department of Surgery, UCSF

bhe@cc.ucsf.edu

Phone: (415) 502-0555
Box 1724, UCSF
San Francisco, CA 94143-1724

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics» Cancer Genetics

Research Summary

The focus of my current research is to define the role of aberrant Hedgehog/Gli activation in chemo and EGFR-TKI resistance in lung cancer and mesothelioma, and to conduct preclinical evaluation of the novel Gli inhibitor that we have recently developed, as potential effective therapeutic treatments to reverse the resistance in lung cancer and mesothelioma. I have also been a PI and co-Investigator of several other research projects funded by NIH and foundations, including identification and validation of novel potential therapeutic targets in lung cancer and mesothelioma; the role of inflammation and epigenetic alterations in lung carcinogenesis; the elucidation of novel molecular mechanisms in lung and mesothelioma carcinogenesis; the identification and validation of prognostic and predictive markers; and the development of small molecule inhibitors of stem cell signaling pathways as potential leads for targeted cancer therapies. As a result, I produced many peer-reviewed publications and issued/pending patents from these projects.

Education

Tsinghua University, Beijing, China, BS, 1993, Biochemistry
Tsinghua University, Beijing, China, MS, 1995, Biochemistry
University of Virginia, VA, PhD, 2001, Molecular, Cell Biology and Genetics
Comprehensive Cancer Center, University of California, San Francisco, CA, Postdoctoral training, 2002, Molecular, Cell Biology and Signal Transduction


Professional Experience

  • 1994-1995
    Graduate Research Assistant, Department of Biology, Tsinghua University, Beijing, China
  • 1995-1996
    Graduate Research Assistant, Biological Timing Center, University of Virginia, VA
  • 1996-1997
    Graduate Teaching Assistant, Department of Biology, University of Virginia, VA
  • 1997-2001
    Graduate Research Assistant, Department of Biology, University of Virginia, VA
  • 2001-2002
    Postdoctoral Researcher, Cancer Center, University of California San Francisco, CA
  • 2002-2004
    Assistant Research Molecular Biologist, Cancer Center, Univ. of California San Francisco, CA
  • 2004-2009
    Assistant Adjunct Professor, Department of Surgery, University of California San Francisco, CA
  • 2009-present
    Associate Adjunct Professor, Department of Surgery, University of California San Francisco, CA

Honors & Awards

  • 1989
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1990
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1991
    Honor of Outstanding Student, Tsinghua University, Beijing, China
  • 1992
    Guanghua Scholarship, Tsinghua University, Beijing, China
  • 1993
    Honor of Outstanding Graduate, Tsinghua University, Beijing, China
  • 1995
    Hua Luogeng Memorial Fellowship, Tsinghua University, Beijing, China
  • 1995
    Fellowship, University of Virginia, Charlottesville, VA
  • 1996
    Fellowship, University of Virginia, Charlottesville, VA
  • 2004
    Barbara Isackson Endowed Research Fellow, University of California, San Francisco, CA
  • 2007
    Eileen Ludwig Award in Thoracic Oncology Research, Univ. of California, San Francisco, CA

Selected Publications

  1. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS One. 2015; 10(7):e0132134.
    View on PubMed
  2. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. Anticancer Res. 2015 Jun; 35(6):3167-73.
    View on PubMed
  3. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma. Oncol Rep. 2015 Apr; 33(4):2052-60.
    View on PubMed
  4. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):465-71.
    View on PubMed
  5. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013 Jun; 22(2):65-9.
    View on PubMed
  6. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene. 2014 Apr 17; 33(16):2087-97.
    View on PubMed
  7. Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One. 2013; 8(3):e57346.
    View on PubMed
  8. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013; 32:7.
    View on PubMed
  9. Molecular markers as therapeutic targets in lung cancer. Chin J Cancer. 2013 Feb; 32(2):59-62.
    View on PubMed
  10. The role of stem cells in airway repair: implications for the origins of lung cancer. Chin J Cancer. 2013 Feb; 32(2):71-4.
    View on PubMed
  11. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
    View on PubMed
  12. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer. 2011 Jul; 12(4):237-44.
    View on PubMed
  13. Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest. Oncol Rep. 2010 Dec; 24(6):1677-81.
    View on PubMed
  14. Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med. 2010 Oct; 4(5):631-45.
    View on PubMed
  15. EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene. 2010 Nov 4; 29(44):5969-75.
    View on PubMed
  16. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene. 2010 Feb 4; 29(5):635-46.
    View on PubMed
  17. The role of cancer stem cells in neoplasia of the lung: past, present and future. Clin Transl Oncol. 2008 Nov; 10(11):719-25.
    View on PubMed
  18. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol. 2008 Oct; 3(10):1089-95.
    View on PubMed
  19. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 1; 14(17):5565-70.
    View on PubMed
  20. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008 Jul; 30(7):946-63.
    View on PubMed

Go to UCSF Profiles, powered by CTSI